British cancer drug developer Ellipses Pharma is exploring a London listing through a reverse takeover by shell company Wolfram Resources, targeting a valuation of £450 million to £500 million.
British cancer drug developer Ellipses Pharma said on Wednesday, November 18, 2026, that it was exploring a London listing through a deal with Wolfram Resources. The company is targeting a valuation of between £450 million and £500 million, with terms yet to be agreed.
The proposal is not completed. Ellipses said it is aiming to complete the transaction by early 2027, and it expects an equity fundraise alongside the deal. The size and pricing of that fundraise were not disclosed.
How the proposed deal works
Wolfram Resources is described as a shell company, and the route is a reverse takeover. In this structure, an operating business combines with an already listed vehicle and takes on its listing, rather than conducting a conventional initial public offering. Wolfram would be the acquirer in the transaction.
The reported valuation range is a target, not an agreed price. Terms have yet to be agreed, so the valuation, the structure and the timetable could all change before any completion.
Who is involved
Ellipses Pharma develops cancer drugs and is based in the United Kingdom. Wolfram Resources is the shell company that would acquire it. Mubadala Investment Company is an indirect shareholder in Wolfram through al-Muhairi. Further details of the ownership arrangement were not disclosed.
The capital behind the plan
Two pieces of capital are in view. The first is the public listing itself, which would give Ellipses a quoted equity currency. The second is the planned equity raise running alongside it. Because no amount has been given, it is not possible to say how much new money the company would receive, or whether existing holders would sell shares.
Why the route matters for founders
For founders in capital-intensive sectors such as biotech, drug development can require funding over long periods before products reach the market. A listing offers access to public investors, and a reverse takeover is one way to reach that market. The facts given do not show why Ellipses chose this route over a traditional offering, and the company's financial position was not disclosed.
The announcement also shows how a listing and a fundraise can be linked. Founders weighing a similar path should understand that a valuation target is only a starting point. It becomes meaningful when investors agree to it, which is why valuation work and defensible assumptions matter before any round. On that theme, see Your Valuation Is Negotiable but Your Financial Assumptions Need to Be Defensible.
Planning a raise of your own? Fundverse can help you prepare materials and find investors whose focus fits your stage and sector.
What to watch next
- Whether Ellipses and Wolfram agree final terms and a valuation.
- The size and pricing of the accompanying equity fundraise.
- Which investors participate in that raise.
- Whether the early-2027 completion target holds.
A single proposed transaction does not show that the sector or the London market is gaining favor with investors. The announcement shows that one company is testing a route to public capital. Whether it succeeds will depend on terms that have not yet been agreed. Founders can read more on the range of capital options in The Investors You Need May Not Be Venture Capitalists.
Frequently asked questions
Topics
Ellipses Pharma
Wolfram Resources
reverse takeover
London listing
biotech IPO
cancer drug developer
equity fundraise
Raising or investing?
Find the right people on the other side of the table, and run the round in one place.

